Roskilly A, Hicks A, Taylor EJ, et al. - Considering that liver fibrosis is the critical determinant of liver‐related findings in people with nonalcoholic fatty liver disease, researchers sought to assess the fibrosis progression rate (FPR) in placebo‐treated nonalcoholic steatohepatitis (NASH) participants in randomised controlled trials (RCTs). Thirty-five trials including 1,419 placebo‐treated participants who underwent repeat liver biopsy were analyzed. According to findings, the FPR is lower in placebo‐treated RCT participants than that described from observational data. The development of slower fibrosis predicts that fewer people with NASH will progress to cirrhosis than previously estimated.